FDA Committee recommends approval of NPs hormone replacement drug natpara

Source: medical geography September 22, 2014 (Reuters) - an external expert committee of the US FDA voted 8:5 on Friday to approve natpara, a hormone replacement therapy drug of NPs pharmaceutical company After the announcement last week, NPs shares have risen about 20% Natpara is a kind of drug used to treat hypoparathyroidism Specifically, the parathyroid gland of the body can not secrete enough parathyroid hormone (PTH), which can regulate the calcium level in the body together with vitamin D When PTH level in human body is low, numbness of fingers and toes, muscle spasm, fatigue, muscle ache, hair loss, dry skin, headache, mood fluctuation and memory problems may occur The low level of PTH can be caused by congenital diseases or surgery At present, high-dose calcium and vitamin D are commonly used in combination, while natpara is the gene engineering drug of PTH According to NPs, there are about 180000 people suffering from hypoparathyroidism in the world, and about 40% of them cannot be controlled by calcium and vitamin D alone This uncontrolled 40% is the group of patients that NPs originally planned to target There are 20000 such patients in the United States Link to the original text: http:// ﹐ f9c4f857-c1eb-4af5-8204-1b9dc1f4e1c5.html